Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform

Published on July 10, 2026
VAUGHAN, Ontario and MENLO PARK, Calif.—Global eye health company Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced the creation of Orphia, a brand-agnostic, AI-powered digital health platform designed to support eyecare providers and improve patient education. Orphia will serve all eyecare providers, regardless of the products, devices or treatments they choose to use, and it will operate under Digital Health Services, a newly-created platform at Bausch + Lomb, the company said in the announcement.
Continue reading on website
Other news

Tarsus Pharmaceuticals Acquires iRenix Medical, Developer of Late-Stage Ocular Antiseptic IRX-101

July 10, 2026
IRVINE, Calif.—Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a biopharmaceutical company focused on therapeutic eyecare, has announced the acquisition of iRenix Medical, Inc., a privately held, clinical-stage ophthalmic biopharmaceutical company and developer of IRX-101, an investigational ocular antiseptic with the potential to reduce post-procedural pain and corneal toxicity in patients receiving

Fielmann Group Releases Preliminary Second Quarter Results, Highlights International Sales Growth, Store Expansion

July 10, 2026
HAMBURG, Germany—Global eyewear provider Fielmann Group announced preliminary consolidated sales of €1.25 billion for the first half of 2026, marking a 2 percent year-over-year increase from €1.23 billion for the first half of 2025. This growth was supported by a modest expansion in Fielmann Germany and a significant acceleration in international sales, which jumped from 1 percent growth in Q1 to